Developing a Nutritional Supplement to Increase Collagen Synthesis in People
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kevin Paulussen, PhD
- Phone Number: 2177214479
- Email: kpaulussen@ucdavis.edu
Study Contact Backup
- Name: Keith Baar, PhD
Study Locations
-
-
California
-
Davis, California, United States, 95616
- Recruiting
- Hickey Laboratory
-
Contact:
- Keith Baar, PhD
- Email: kbaar@ucdavis.edu
-
Contact:
- Kevin Paulussen, PhD
- Email: kpaulussen@ucdavis.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Young healthy adults (18-30 y)
Exclusion Criteria:
- Pregnancy
- Smoking
- Receiving any medication that may interfere with the study outcomes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Natural Product Supplement
The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg), epicatechin (75 mg), vitamin E (350 iU) and stevia extract (225 mg).
|
Participants will have blood drawn before and one hour after consuming the natural product supplement.
For 7-days the participants will perform load-bearing exercise and consume the supplement.
On the final day, blood will be collected 4 hours after the final exercise bout.
|
|
Placebo Comparator: Placebo
The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg) and sweetener.
|
Participants will have blood drawn before and one hour after consuming the placebo supplement.
For 7-days the participants will perform load-bearing exercise and consume the supplement.
On the final day, blood will be collected 4 hours after the final exercise bout.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collagen protein synthesis
Time Frame: 7 days
|
Collagen protein synthesis will be indirectly measured by measuring pro-collagen type I N-terminal propeptide (PINP) in the serum before and 4 hours after the last exercise bout (at day 7 of the protocol).
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Strength of ligament constructs
Time Frame: 60 minutes post-exercise
|
Serum from participants will be used to treat engineered ligaments in order to measure the effect of the supplementation on the strength of the ligaments.
The strength will be measured using the Instron bio puls 68SC-1 tension and compression machine.
|
60 minutes post-exercise
|
|
Collagen content of ligament constructs
Time Frame: 60 minutes post-exercise
|
Ligament constructs will be treated for 7 days with experimental feed medium containing serum obtained at baseline or post-prandial for determination of collagen content using a hydroxyproline assay.
|
60 minutes post-exercise
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Keith Baar, PhD, University of California, Davis
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2110494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.